LITFULO Meets Both Pivotal Vitiligo Endpoints
Two Phase 3 trials of oral ritlecitinib in nonsegmental vitiligo met their U.S. co-primary Week-52 endpoints for facial and total-body repigmentation. Pfizer plans global submissions for adults. The topline release establishes pivotal success but…
